Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials.
Ledenko M, Antwi SO, Arima S, Driscoll J, Furuse J, Klümpen HJ, Larsen FO, Lau DK, Maderer A, Markussen A, Moehler M, Nooijen LE, Shaib WL, Tebbutt NC, André T, Ueno M, Woodford R, Yoo C, Zalupski MM, Patel T. Ledenko M, et al. Among authors: maderer a. Front Oncol. 2022 Aug 11;12:963753. doi: 10.3389/fonc.2022.963753. eCollection 2022. Front Oncol. 2022. PMID: 36033540 Free PMC article. No abstract available.
Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
Moehler M, Thomaidis T, Zeifri C, Barhoom T, Marquardt J, Ploch P, Schattenberg J, Maderer A, Schimanski CC, Weinmann A, Woerns MA, Kranich AL, Warnecke JM, Galle PR. Moehler M, et al. Among authors: maderer a. J Cancer Res Clin Oncol. 2015 Mar;141(3):515-22. doi: 10.1007/s00432-014-1829-6. Epub 2014 Sep 19. J Cancer Res Clin Oncol. 2015. PMID: 25230900
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.
Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T. Moehler M, et al. Among authors: maderer a. BMC Cancer. 2019 Jan 11;19(1):55. doi: 10.1186/s12885-018-5223-7. BMC Cancer. 2019. PMID: 30634942 Free PMC article. Clinical Trial.
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thomaidis T, Maderer A, Al-Batran SE, Kany J, Pauligk C, Steinmetz K, Schad A, Hofheinz R, Schmalenberg H, Homann N, Galle PR, Moehler M. Thomaidis T, et al. Among authors: maderer a. BMC Cancer. 2014 Jul 1;14:476. doi: 10.1186/1471-2407-14-476. BMC Cancer. 2014. PMID: 24981311 Free PMC article. Clinical Trial.
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
Wehler TC, Hamdi S, Maderer A, Graf C, Gockel I, Schmidtmann I, Hainz M, Berger MR, Theobald M, Galle PR, Moehler M, Schimanski CC. Wehler TC, et al. Among authors: maderer a. Int J Colorectal Dis. 2013 Mar;28(3):385-98. doi: 10.1007/s00384-012-1551-2. Epub 2012 Sep 15. Int J Colorectal Dis. 2013. PMID: 22983756 Free PMC article.
26 results